< LEADERBOARD/s/l-carnitineSports & ergogenics

L-Carnitine

Also sold as: Levocarnitine · Acetyl-L-carnitine · ALCAR · L-carnitine L-tartrate · Propionyl-L-carnitine

Carnitine supports mitochondrial fatty-acid transport. Different forms have clinical research in male infertility, claudication and neurological conditions, while healthy-user fat-loss, energy and cognitive claims are much less convincing.

Focus Energy Longevity

COMMUNITY_STACK_RATINGlive · n=0

Community

Not enough ratings yet: 0 of 10

Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.

+ Rate your experience (30 sec, anonymous)

NERD_PROTOCOL // EVIDENCE_MATRIXper goal

Research

FocusLimited · no benefit EnergyLimited · benefit LongevityLimited · benefit

Focus: No convincing cognitive-enhancement benefit is established in healthy people; small older MCI/early-Alzheimer signals belong to ALCAR and clinical populations.
Energy: Fatigue trials in centenarians and selected clinical populations suggest benefit; this does not generalize to rested young adults or an immediate pre-workout effect.
Longevity: Older post-MI studies found a borderline mortality signal, not established life extension; contemporary outcome confirmation and TMAO uncertainties remain.

REALITY CHECK // Carnitine is not a reliable rapid fat burner or nootropic for everyone. Clinical populations and ester forms drive many positive studies. Older post-MI benefit signals coexist with TMAO concerns, and neither proves a universal cardiovascular benefit or that oral supplements cause heart attacks.

Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.

Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.

CHECK_YOUR_BOTTLE.EXEruns in your browser · nothing is sent or stored

Check your bottle

Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.

Enter the amount from your label to see the result.

How it was studied

01 // STUDIED_DOSE_RANGE

Form and population matter

Source ranges vary by endpoint: weight-management trials 0.6-4 g/day LC; centenarian fatigue trial 2 g/day; ALCAR cognitive trials 1.5-3 g/day for 3-12 months; PLC claudication trials 1 g twice daily. Older post-MI studies used around 6 g/day, a medical context rather than a routine target.

02 // TIMING_&_MATRIX

Administration context

Carbohydrate/insulin can affect muscle retention, not simply intestinal absorption. Chronic saturation, specific form and clinical endpoint matter; a single pre-workout dose is not established effective. Evening ALCAR can feel activating in anecdotal reports.

03 // EVALUATION_WINDOW

Match the studied window

Infertility protocols often span 3-6 months; ALCAR cognitive trials 3-12 months. Exercise reviews distinguish chronic from acute use. Cardiovascular findings are not general longevity trials.

04 // SAFETY_&_QUALITY_GATE

Review limits and medicines

No formal EFSA/NIH UL is established. Around 2 g/day is commonly tolerated; higher trial doses are not a universal safety ceiling. GI effects, fishy odor and unresolved chronic TMAO implications limit casual dose escalation. Review use with hypothyroidism/levothyroxine, vitamin K antagonists, epilepsy, major kidney disease, pregnancy or lactation and high cardiovascular risk. Injections are medical procedures, not a home fat-loss protocol. GI upset and fishy odor become more likely at high doses.

UPPER LIMIT // No formal EFSA/NIH UL is established. Around 2 g/day is commonly tolerated; higher trial doses are not a universal safety ceiling. GI effects, fishy odor and unresolved chronic TMAO implications limit casual dose escalation.

NERD'S NOTENerd Protocols · a clinical and sports dietitian based in the EU

Summary

The strongest signals are form- and population-specific: combined LC/ALCAR in idiopathic male infertility and propionyl-L-carnitine in intermittent claudication. Weight reduction averages about 1.2 kg in mainly overweight/metabolic populations. Healthy cognition and acute athletic-energy claims are unconvincing.

Mechanism

Carnitine shuttles long-chain fatty-acid groups into mitochondria. Acetyl and propionyl derivatives have distinct metabolic roles. Gut microbial conversion to TMA/TMAO raises a plausible vascular concern, but supplement-to-heart-attack causality has not been established in humans.

Typical studied dose

Upper limit

POPULAR_STACKScombos with n ≥ 5

Popular stacks with L-Carnitine

Not enough stack data yet. A combination with L-Carnitine appears here once 5 people rate the same set.

> Rate my stack

Forms and label traps

Forms compared
Form on label	Active content	Studied range / day	Absorption & GI tolerance	Verdict
Free L-carnitine / levocarnitine Best for: Matching LC-specific metabolic trial mass.	Extract weight · ~100% marker	600–4000 mg	Supplemental oral absorption about 14-18%; dietary absorption is higher. Nausea, cramps, diarrhea and fishy odor may occur.	Studied standard [FORM // REFERENCE] 100% describes free compound mass, not absorption. Trial doses vary by endpoint; this broad interval is not a single optimal dose. PMID 12908852 PMID 32359762
L-carnitine L-tartrate (LCLT) Best for: Exercise-recovery research.	68% elemental / active	no comparable trial range	Salt used in recovery studies; no absorption-equivalence multiplier. Similar GI and odor concerns at high intake.	Good option [FORM // CHECK_BASIS] Approximately 68% carnitine by compound mass is composition, not bioavailability. A form-specific carnitine-basis trial interval is not supplied, so comparator remains unavailable. PMID 32154768 PMID 29534031
Acetyl-L-carnitine (ALCAR), full active compound mass Best for: MCI/early-Alzheimer research, not healthy nootropic proof.	Extract weight · marker not quantified	1500–3000 mg	Acetyl derivative with CNS-related clinical research. GI effects; anecdotal activation or insomnia.	Good option [FORM // CHECK_BASIS] Compare full ALCAR mass used in trials. Do not reduce trial doses by an 80% carnitine-moiety estimate; salts must disclose active ALCAR separately. PMID 12598816 PMID 31201734
Propionyl-L-carnitine (PLC), full active compound mass Best for: PAD claudication evidence.	Extract weight · marker not quantified	2000–2000 mg	Vascular/muscle derivative studied in claudication. Generally tolerated in studied clinical settings.	Good option [FORM // CHECK_BASIS] PLC 1 g twice daily is a full-compound trial regimen. It is not equivalent to GPLC or ordinary LC after a 74% conversion. PMID 23321261 PMID 34954832

Common label traps

TRAP_01 // Carnitine burns fat immediately
A 37-RCT synthesis found about -1.21 kg average weight difference, mainly in overweight/metabolic populations; no waist or body-fat-percentage benefit was established.
TRAP_02 // ALCAR improves focus in every healthy brain
Small old MCI/early-Alzheimer findings do not establish benefit in cognitively healthy people.
TRAP_03 // Oral absorption is low, so injections are better
Bypassing absorption does not prove better fat-loss or cardiovascular outcomes and introduces procedural, sterility and sourcing risks.
TRAP_04 // LCLT is a testosterone booster
Receptor-related marketing is not proof of meaningful hormonal, libido or performance benefit in healthy users.

Other outcomes studied

Outside the five leaderboard goals. Same evidence levels as above.

MALE INFERTILITY Moderate · benefit
Seven RCTs / 693 patients using combined LC+ALCAR: progressive motility MD 6.98 percentage points (95% CI 1.06-12.90), pregnancy OR 3.76 (1.66-8.50); not all semen measures improved. Applies to idiopathic infertility, not healthy fertility boosting.
PMID 31701550 PMID 35128424 PMID 40813743
INTERMITTENT CLAUDICATION Moderate · benefit
PLC patient-level synthesis found about +16 m peak walking distance versus placebo; broader pooling about +45 m. This form-specific clinical PAD effect is modest.
PMID 23321261 PMID 34954832
CHRONIC HEART FAILURE Limited · benefit
Seventeen RCTs / 1625 patients: LVEF about +4.14 percentage points and biomarker changes, but no significant mortality or six-minute-walk benefit; bias and study-quality concerns.
PMID 28497060
POST-MI SECONDARY PREVENTION Limited · benefit
Older 13-study synthesis / 3629 patients: mortality OR 0.73 (95% CI 0.54-0.99), ventricular arrhythmia RR 0.35, angina RR 0.60; reinfarction and heart-failure outcomes not significant. Contemporary confirmation is missing.
PMID 23597877 PMID 25044037
DIABETIC NEUROPATHY Limited · benefit
Cochrane ALCAR review found low-certainty pain evidence in a heterogeneous clinical corpus; not routine self-treatment.
PMID 31201734
MCI / EARLY ALZHEIMER DISEASE Limited · benefit
Older ALCAR meta-analysis reported integrated ES 0.201 (95% CI 0.107-0.295) over 3-12 months. A small clinical-population signal, not healthy enhancement.
PMID 12598816 PMID 12804452
CLINICAL FATIGUE Limited · benefit
LC 2 g/day in centenarians and ALCAR studies in hepatic encephalopathy suggest improvement; younger rested users and all fatigue disorders are not represented.
PMID 18065594 PMID 12875611 PMID 21310833 PMID 30610762
EXERCISE PERFORMANCE Limited · no benefit
An 11-study review found mixed form-, intensity- and duration-dependent results rather than a consistent ergogenic effect. Acute use is not established.
PMID 34959912
EXERCISE MUSCLE DAMAGE Limited · benefit
Seven-RCT synthesis suggests reductions in damage markers; small studies and surrogate endpoints do not guarantee faster functional recovery.
PMID 32154768 PMID 29534031
BODY WEIGHT Limited · benefit
Thirty-seven RCTs / 2292 participants: weight WMD -1.21 kg (95% CI -1.73 to -0.68), BMI -0.24 kg/m2, fat mass -2.08 kg; waist and body-fat percentage not significant. Mainly overweight/metabolic populations.
PMID 32359762 PMID 31743774 PMID 27335245
TMAO / VASCULAR SAFETY Limited · makes it worse
Human microbiome/exposure findings and mouse atherosclerosis models raise concern; observational TMAO associations do not establish causal supplement-induced cardiovascular events.
PMID 23563705 PMID 24267266 PMID 31073588

Reader questions

Which form is best for my goal?

ALCAR has neurological clinical research, PLC has claudication trials, and LC/LCLT appear in metabolic/recovery research. These cannot be exchanged using a single carnitine-equivalent efficacy number.

Does it really help weight loss?

The pooled average is small, about 1.2 kg, largely in overweight or metabolic populations. That does not establish a useful fat-burning effect in lean active people.

Why the fishy body odor?

Microbial trimethylamine generation can contribute, particularly at higher intake. Odor and diarrhea are reasons to reassess use rather than escalate.

Is it useful before IVF?

Combined LC/ALCAR has infertility signals, but infertility needs evaluation and outcome tracking with an appropriate clinician; it is not a universal fertility booster.

Should I inject it instead?

No home injection protocol is supported here. Clinical injections require medical indication, sterile sourcing and professional supervision.

Stack interactions

Caution Levothyroxine and thyroid disease [CAUTION // REVIEW_CONTEXT]
Carnitine is a peripheral antagonist of thyroid hormone action. A hyperthyroidism trial is not a hypothyroidism benefit; review symptoms and thyroid monitoring when treated with levothyroxine.
PMID 11502782 PMID 15591013
Caution Warfarin / acenocoumarol [CAUTION // REVIEW_CONTEXT]
Increased INR has been described in interaction resources and case reports, but strong primary evidence is absent in this dossier. Discuss monitoring with the anticoagulation team.
Caution Choline and lecithin [CAUTION // REVIEW_CONTEXT]
These and carnitine can feed microbial TMA/TMAO pathways. Clinical harm from a particular stack is not proven, but high-dose stacking is not justified as automatically heart-protective.
PMID 23563705 PMID 31073588
Caution Valproate and pivalate antibiotics [CAUTION // REVIEW_CONTEXT]
These drugs can deplete carnitine; the direction is drug-to-nutrient. Clinician-directed replacement is different from claiming carnitine interferes with antibiotic efficacy.
Caution CoQ10 / alpha-lipoic acid [CAUTION // REVIEW_CONTEXT]
CoQ10 and carnitine have clinical infertility research; mitochondrial ALCAR/ALA synergy remains mainly preclinical or preliminary, not general anti-aging proof.
PMID 40813743

Red flags: interactions and who should avoid it

Interactions

Levothyroxine and thyroid disease: Carnitine is a peripheral antagonist of thyroid hormone action. A hyperthyroidism trial is not a hypothyroidism benefit; review symptoms and thyroid monitoring when treated with levothyroxine. Warfarin / acenocoumarol: Increased INR has been described in interaction resources and case reports, but strong primary evidence is absent in this dossier. Discuss monitoring with the anticoagulation team. Choline and lecithin: These and carnitine can feed microbial TMA/TMAO pathways. Clinical harm from a particular stack is not proven, but high-dose stacking is not justified as automatically heart-protective. Valproate and pivalate antibiotics: These drugs can deplete carnitine; the direction is drug-to-nutrient. Clinician-directed replacement is different from claiming carnitine interferes with antibiotic efficacy. CoQ10 / alpha-lipoic acid: CoQ10 and carnitine have clinical infertility research; mitochondrial ALCAR/ALA synergy remains mainly preclinical or preliminary, not general anti-aging proof.

Avoid or ask a doctor first if

Review use with hypothyroidism/levothyroxine, vitamin K antagonists, epilepsy, major kidney disease, pregnancy or lactation and high cardiovascular risk. Injections are medical procedures, not a home fat-loss protocol. GI upset and fishy odor become more likely at high doses.

Sources (PubMed, 28)

The efficacy of combined l-carnitine and l-acetyl carnitine in men with idiopathic oligoasthenoteratozoospermia: A systematic review and meta-analysis.
PMID 31701550 · 2020 · systematic review / meta-analysis
Combined LC/ALCAR infertility endpoints and pregnancy signal.
l-carnitine and l-acetylcarnitine supplementation for idiopathic male infertility.
PMID 35128424 · 2020 · systematic review / meta-analysis
Clinical idiopathic male infertility synthesis.
Effects of Carnitine and Coenzyme Q10 on Sperm Quality and Pregnancy Rates in Men with Unexplained Infertility: A Systematic Review and Network Meta-Analysis.
PMID 40813743 · 2025 · systematic review / meta-analysis
Network synthesis of carnitine and CoQ10 infertility outcomes.
A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.
PMID 23321261 · 2013 · systematic review / meta-analysis
PLC-specific claudication walking-distance effects.
Propionyl-L-carnitine for intermittent claudication.
PMID 34954832 · 2021 · systematic review / meta-analysis
Cochrane intermittent-claudication evidence.
Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials.
PMID 28497060 · 2017 · systematic review / meta-analysis
Heart-failure surrogate improvements without significant mortality benefit.
L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis.
PMID 23597877 · 2013 · systematic review / meta-analysis
Older borderline post-MI mortality and arrhythmia signal.
Effective dosing of L-carnitine in the secondary prevention of cardiovascular disease: a systematic review and meta-analysis.
PMID 25044037 · 2014 · systematic review / meta-analysis
Post-MI dosing context, not a routine target.
Acetyl-L-carnitine for the treatment of diabetic peripheral neuropathy.
PMID 31201734 · 2019 · systematic review / meta-analysis
Low-certainty ALCAR diabetic-neuropathy evidence.
Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease.
PMID 12598816 · 2003 · systematic review / meta-analysis
Small ALCAR MCI/early-Alzheimer signal.
Acetyl-L-carnitine for dementia.
PMID 12804452 · 2003 · systematic review / meta-analysis
Cochrane dementia limitations.
L-carnitine for cognitive enhancement in people without cognitive impairment.
PMID 28349514 · 2017 · systematic review / meta-analysis
No convincing healthy cognitive-enhancement evidence.
L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: a randomized and controlled clinical trial.
PMID 18065594 · 2007 · randomized controlled trial
Centenarian fatigue trial, not young healthy energy.
Levocarnitine administration in elderly subjects with rapid muscle fatigue: effect on body composition, lipid profile and fatigue.
PMID 12875611 · 2003 · randomized controlled trial
Selected older-adult fatigue findings.
Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.
PMID 21310833 · 2011 · randomized controlled trial
ALCAR fatigue trial in hepatic encephalopathy.
Acetyl-L-carnitine for patients with hepatic encephalopathy.
PMID 30610762 · 2019 · systematic review / meta-analysis
Hepatic-encephalopathy evidence context.
Effect of Acute and Chronic Oral l-Carnitine Supplementation on Exercise Performance Based on the Exercise Intensity: A Systematic Review.
PMID 34959912 · 2021 · systematic review / meta-analysis
Mixed acute/chronic exercise findings across forms.
The Effect of L-Carnitine Supplementation on Exercise-Induced Muscle Damage: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
PMID 32154768 · 2020 · systematic review / meta-analysis
Small-study muscle-damage marker synthesis.
l-Carnitine Supplementation in Recovery after Exercise.
PMID 29534031 · 2018 · narrative review
Recovery research and endpoint limits.
Effects of l-carnitine supplementation on weight loss and body composition: A systematic review and meta-analysis of 37 randomized controlled clinical trials with dose-response analysis.
PMID 32359762 · 2020 · systematic review / meta-analysis
Small weight/body-composition effects in 37 RCTs.
Beneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 31743774 · 2020 · systematic review / meta-analysis
Overweight/obesity dose-response review.
The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials.
PMID 27335245 · 2016 · systematic review / meta-analysis
Small adult weight-loss effect.
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
PMID 23563705 · 2013 · animal / mechanistic study
Microbiome/TMAO and animal atherosclerosis mechanism; not human event causality.
Gut microbiota metabolism of L-carnitine and cardiovascular risk.
PMID 24267266 · 2013 · narrative review
TMAO cardiovascular-risk interpretation.
Modulation of Circulating Trimethylamine N-Oxide Concentrations by Dietary Supplements and Pharmacological Agents: A Systematic Review.
PMID 31073588 · 2019 · systematic review / meta-analysis
Supplement-induced TMAO modulation review.
Pharmacokinetics of L-carnitine.
PMID 12908852 · 2003 · narrative review
Oral pharmacokinetics and absorption limits.
Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial.
PMID 11502782 · 2001 · randomized controlled trial
Thyroid hormone antagonism in iatrogenic hyperthyroidism.
Effects of carnitine on thyroid hormone action.
PMID 15591013 · 2004 · randomized controlled trial
Thyroid-hormone action context.

Community comments

No approved comments yet. Comments are held for moderation.

+ Rate this